ProCE Banner Activity

Key HIV Studies Influencing My Practice Following IDWeek and HIV Glasgow 2022—Joseph J. Eron, Jr., MD, and Karine Lacombe, MD, PhD

Multimedia

Hear from expert faculty as they present their insights on some of the most clinically relevant new data presented at IDWeek and HIV Glasgow 2022, including prevention strategies, long-acting therapies, and investigational agents.

Released: November 30, 2022

Share

Faculty

Joseph J. Eron

Joseph J. Eron, Jr., MD

Professor of Medicine
University of North Carolina School of Medicine
Director, AIDS Clinical Trials Unit
University of North Carolina
Chapel Hill, North Carolina

Karine Lacombe

Karine Lacombe, MD, PhD

Professor of Medicine
Infectious Diseases Department
Sorbonne Uiversité
Inserm Pierre Louis School of Public Health
Paris, France

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

ViiV Healthcare

Faculty Disclosure

Primary Author

Joseph J. Eron, Jr., MD

Professor of Medicine
University of North Carolina School of Medicine
Director, AIDS Clinical Trials Unit
University of North Carolina
Chapel Hill, North Carolina

Joseph J. Eron, Jr., MD: consultant/advisor/speaker: Gilead Sciences, GlaxoSmithKline, Janssen, Merck, ViiV Healthcare; researcher: Gilead Sciences, ViiV Healthcare.

Karine Lacombe, MD, PhD

Professor of Medicine
Infectious Diseases Department
Sorbonne Uiversité
Inserm Pierre Louis School of Public Health
Paris, France

Karine Lacombe, MD, PhD: consultant/advisor/speaker: Gilead Sciences, GlaxoSmithKline, Janssen, MSD.